The secreted protein S100A7 (psoriasin) is induced by telomere dysfunction in human keratinocytes independently of a DNA damage response and cell cycle regulators
© de Castro et al.; licensee BioMed Central Ltd. 2014
Received: 27 June 2014
Accepted: 3 October 2014
Published: 17 October 2014
Replicative senescence is preceded by loss of repeat sequences of DNA from the telomeres that eventually leads to telomere dysfunction, the accumulation of irreparable DNA double strand breaks and a DNA damage response (DDR). However, we have previously reported that whilst telomere dysfunction in human keratinocytes is associated with a permanent cell cycle arrest, the DDR was very weak and transcriptional profiling also revealed several molecules normally associated with keratinocytes terminal differentiation, including S100A7 (psoriasin).
We show here that S100A7 and the closely related S100A15 (koebnerisin) are not induced by repairable or irreparable DSBs, ruling out the hypotheses that these genes are induced either by the low DDR observed or by non-specific cell cycle arrest. We next tested whether S100A7 was induced by the cell cycle effectors ARF (p14ARF), CDKN2A (p16INK4A) and TP53 (p53) and found that, although all induced a similar level of acute and permanent cell cycle arrest to telomere dysfunction, none induced S100A7 (except p53 over-expression at high levels), showing that cell cycle arrest is not sufficient for its induction. The closely related transcript S100A15 was also upregulated by telomere dysfunction, to a similar extent by p16INK4A and p53 and to a lesser extent by p14ARF.
Our results show that mere cell cycle arrest, the upregulation of senescence-associated cell cycle effectors and DNA damage are not sufficient for the induction of the S100 transcripts; they further suggest that whilst the induction of S100A15 expression is linked to both telomere-dependent and -independent senescence, S100A7 expression is specifically associated with telomere-dependent senescence in normal keratinocytes. As both S100A7 and S100A15 are secreted proteins, they may find utility in the early detection of human keratinocyte telomere dysfunction and senescence.
KeywordsTelomere Senescence Keratinocyte Differentiation SASP S100
Senescence is defined as a permanent cell cycle arrest that occurs following extensive cell divisions (replicative senescence, RS) or more acutely following a variety of cellular stresses (stress- or proliferation-induced senescence). In addition to engaging a permanent cell cycle arrest, senescent cells secrete a variety of proteins known as the senescence-associated secretory phenotype (SASP) or senescence-messaging-secretome [1, 2]. These types of proteins are of extra interest because they may find a use in the non-invasive detection of senescent cells in ageing and other pathologies .
RS occurs following extensive rounds of cell division and is accompanied by the erosion of the chromosomal telomeres . Telomeres are repeat sequences of DNA, TTAGGG and their associated proteins, which are known as the shelterin complex [5, 6] and protect the DNA ends from being perceived by the cell as a DNA double strand break (DSB). Telomeres will shorten when cells divide in the absence of telomerase due to either the end replication problem [4, 7, 8], exonuclease digestion  or, in some circumstances, oxidative damage [10, 11]. This culminates in the telomere being perceived as a DSB  and most senescent cells mount a significant DDR . In addition, the G-rich telomere sequences are susceptible to oxidative damage and very inefficient at non-homologous end-joining repair leading to a preferential accumulation of irreparable DSBs (IrrDSBs) at the telomere [14, 15]. Telomerase is deregulated in most human cancers including oral squamous cell carcinoma (OSCC ) and can immortalise normal and neoplastic keratinocytes that lack the expression of the INK4A locus or a combination of p53 and p16INK4A proteins by lengthening the telomeres and restoring their function . Telomerase has also been reported to remove the IrrDSBs at telomeres, but it is not clear whether this property is related to its canonical telomere-lengthening function .
Although keratinocyte stem cells are not thought to decrease in number during in vivo ageing , there is considerable evidence that they undergo an age-related loss of function (reviewed in ); as with increased chronological age, their progeny display increased levels of stochastic senescence in vitro telomeric attrition [22–24] and an accumulation of p16INK4A[25, 26], the last of which is reported to be inversely associated with longevity .
Telomere dysfunction and its associated DDR can be induced along with senescence by over-expressing a dominant-negative mutant of the shelterin protein telomere-repeat binding factor 2 (TRF2), TRF2 delta B delta M (TRF2 ΔBΔM or TRF2DN) . However, although this manipulation induces permanent cell cycle arrest  and leads to underphosphorylated pRb (Minty and Parkinson, unpublished data), it does not generate a strong DDR in normal human keratinocytes, as exemplified by a lack of strong induction of p53 phosphorylation at serine 15, or 53BP1 foci and no detectable increase in p21WAF or SMC1-phosphoS966 or Nbs1-phosphoS343 (Minty and Parkinson, unpublished data). In contrast, all of these DDR markers were induced by 8–16 gray of ionising radiation in a dose-dependent manner and p53 stabilisation by as low a dose as 1 gray ( and Minty and Parkinson, unpublished data). Similar results are seen when a neoplastic keratinocyte line, D17, lacking expression of p16INK4A undergoes RS and telomere shortening . Instead, in both situations, we observed an induction of several genes normally associated with keratinocyte terminal differentiation, including HOPX and S100A7 and other genes not obviously related to differentiation (ICEBERG and the histone HIST2H2BE); in D17, we also observed a reduction in expression of all of these genes upon expression of telomerase in parallel with telomere lengthening, senescence bypass and an elimination of the very small increase in p53 phosphorylation at serine 15 . As these genes showed potential as markers of telomere dysfunction, we investigated them further.
Our earlier work stimulated the hypothesis that signals other than DNA double strand breaks and the DDR could be generated from dysfunctional telomeres to increase the expression of proteins that might have diagnostic use. S100A7 was of particular interest as its encoded protein is secreted by keratinocytes and is found in detectable amounts in human serum where it has found utility as a non-invasive marker of a subtype of lung cancer .
Alternatively, the small DDR observed in keratinocytes following telomere uncapping or shortening might be enough to induce the terminal differentiation genes. Indeed, DNA damage has been shown to contribute to tissue ageing by the induction of terminal differentiation . To test this hypothesis, we examined the effects of both low- and high-dose ionising radiation [28, 31] on the expression of the genes induced by telomere dysfunction and showed that S100A7 was not increased in expression relative to the non-irradiated controls.
Additionally, the increased expression of keratinocyte differentiation genes could be a consequence of any form of senescence or growth arrest. To test this hypothesis and to investigate the role of the cell cycle proteins involved in senescence, we ectopically expressed ARF (p14ARF), CDKN2A (p16INK4a) and TP53 (p53) in human keratinocytes and showed that, despite similar levels of growth arrest, these manipulations did not induce the expression of S100A7 (except for high levels of p53), although all three induced the expression of the S100A15 (koebnerisin) gene, which is highly homologous to S100A7 (psoriasin) and difficult to discriminate when co-regulated. Their differential regulation by cell cycle inhibitors suggests that both S100 proteins have different functions that need to be further studied.
As the S100A7 protein was potentially a specific marker of telomere dysfunction, we investigated this further and showed it to be increased in normal keratinocytes following the induction of telomere dysfunction by the dominant-negative TRF2 construct TRF2 ΔBΔM .
Results and discussion
Markers of keratinocyte telomere dysfunction are not induced by DNA double strand breaks
In order to test whether the small DDR observed following keratinocyte telomere uncapping or shortening  was responsible for the induction of HIST2H2BE, ICEBERG, HOPX and S100A7, we exposed normal human keratinocytes to 2, 10 or 20 gray of ionising radiation (IR). All of these doses have been shown by ourselves ( and Minty and Parkinson, unpublished data) and others  to generate a strong DDR.
The induction of permanent growth arrest by the cell cycle effectors ARF/p14ARF, CDKN2A/p16INK4A and TP53/p53 does not replicate the effect of TRF2 ΔBΔM on the expression of HIST2H2BE, ICEBERG, HOPX and S100A7
Distinct response of S100A7 and S100A15to telomere dysfunction and inducers of senescence
We previously reported that inducing telomere dysfunction in newborn human keratinocytes induced growth arrest and increased the expression of several genes, HIST2H2BE, ICEBERG, HOPX and S100A7, within 5 days, despite eliciting a very weak DDR that is typical of most cell types . HIST2H2BE, ICEBERG, HOPX and S100A7 were also expressed when a p16INK4A-deficient dysplasia line (D17) underwent replicative senescence and telomere shortening in the absence of a strong DDR, and these four transcripts were shown to be reduced upon the ectopic expression of the catalytic component of telomerase, telomere lengthening and elimination of the weak DDR .
The above experiments suggested that the four candidate genes HIST2H2BE, ICEBERG, HOPX and S100A7 could be highly specific and early markers of keratinocyte telomere dysfunction, but several questions remained unanswered. For instance, it was possible that keratinocytes were unusually sensitive to the DDR, and that the weak DDR we observed was enough to induce the transcription of HIST2H2BE, ICEBERG, HOPX and S100A7. To test this, we subjected keratinocytes to both a low dose (2 gray) of γ irradiation that had been calculated to simulate the uncapping of 92 telomeres, and higher doses (10 or 20 gray) that had been reported to induce human cellular senescence and a strong DDR . However, only HIST2H2BE was shown to be induced by γ irradiation. This is consistent with recent reports showing that chromatin components, such as H2A and H2B histones, are actively involved in the response to DNA damage [37, 38]. HIST2H2BE is thus an active participant in the DDR and not a specific marker of telomere dysfunction-induced keratinocyte permanent growth arrest. In contrast, ICEBERG, HOPX and S100A7 were not induced even by a strong DDR or indeed permanent growth arrest.
To further test the specificity of ICEBERG, HOPX and S100A7 to telomere dysfunction, we induced permanent growth arrest in a different way: by the ectopic expression of the transcripts encoding the cell cycle inhibitors p14ARF, p16INK4A and p53. This experiment had the dual purpose of testing the specificity of the above genes and also whether the cell cycle effectors were sufficient to induce them. The expression of p53 and p14ARF did induce ICEBERG expression, although the effect of p53 was highly variable, and p53 induced HOPX. The result with p53 is a little difficult to reconcile with the absence of the induction of ICEBERG and HOPX following γ irradiation, but we have consistently failed to observe a large increase in total p53 protein in human keratinocytes following γ irradiation or telomere dysfunction and so the induction of ICEBERG and HOPX by p53 may be limited to situations such as UV exposure where p53 is stabilised and strongly over-expressed in human keratinocytes .
However, no transgene, except TRF2 ΔBΔM , induced S100A7 expression, and for this reason, we pursued S100A7 as a potential early biomarker of telomere dysfunction in the absence of DNA double strand breaks. This result is also similar to that obtained for several SASP proteins, which are also not induced by the ectopic expression of the cell cycle regulator and effector of senescence, p16INK4A. S100A7 was over-expressed both at the transcript and protein level following telomere uncapping by ectopic expression of TRF2 ΔBΔM .
TRF2 has been reported to be over-expressed in both basal and squamous cell carcinomas of the skin  and very recently has been shown to regulate the recruitment of natural killer cells by a cell extrinsic mechanism . However, our earlier work showed that whilst the over-expression of TRF2 at high levels did cause keratinocyte growth arrest it induced a distinct gene expression profile from TRF2 ΔBΔM that did not include S100A7 (Minty et al., unpublished data). These data argue against our results being the consequence of TRF2 over-expression as opposed to telomere uncapping.
During the course of the study, we became aware that the primers used to detect S100A7 (psoriasin) also detected a closely related gene S100A15 (koebnerisin). Koebnerisin, unlike psoriasin, is expressed in the epidermal basal layer and in cell types other than keratinocytes. However, when we used specific primers for S100A7 and S100A15 transcripts, we found that the major S100 transcript specifically induced by telomere dysfunction was S100A7 and that the expression of S100A15 was very low. However, interestingly S100A15 did seem to also be induced by the ectopic expression of p16INK4A and p53; p16INK4A is over-expressed in senescent keratinocytes in vitro and increases in the epidermis of elderly humans [25, 26] where it is also inversely associated with long-lived families  and it will be interesting to test whether S100A15 follows a similar expression pattern to p16INK4A in the epidermis of elderly subjects.
S100 proteins can participate in the squamous epithelial barrier as part of the cornified envelope, and S100A15 (koebnerisin) and S100A7 (psoriasin) both attracted interest because of their association with psoriasis. When released into the extracellular space, they synergise to participate in the innate immune response by acting as antimicrobial agents and by acting as chemoattractants for auxiliary immune cells and act as pro-inflammatory cytokines to amplify the immune response . In normal skin, S100A7 (psoriasin) and S100A15 (koebnerisin) are both expressed by terminally differentiated keratinocytes of the upper epidermis, which are not replicative . In contrast to psoriasin, koebnerisin is also produced by most cells in the basal epidermal layer, which might reflect the fact that most of the basal keratinocytes are non-dividing. Thus, koebnerisin could be a negative marker of replicating epidermal stem cells in the skin, which requires further investigation.
S100A7 (psoriasin) is upregulated in the early stages of tumour progression, where in its cytoplasmic form it has been reported to inhibit beta catenin signalling and act as a tumour suppressor in both breast epithelial cells  and keratinocytes . S100A7 is downregulated when premalignant keratinocytes bypass senescence and is downregulated in the invasive parts of tumours in vivo. In contrast, in its secreted form, S100A7 binds to the receptor of advanced glycation endproducts (RAGE) on neighbouring tumour cells and can activate nuclear factor kappa B  and hence possibly members of the SASP  in neighbouring cells, including matrix metalloproteinases  and a variety of cytokines and other molecules . Thus, S100A7 may mediate the effects of telomere dysfunction by first acting as a tumour suppressor intracellularly but may also act as a keratinocyte-specific SASP protein that can also spread its effects to neighbouring cells and as such may modulate to both ageing and tumour progression.
S100A7 protein is also detectable in human serum and as such might turn out to have potential as a non-invasive marker of keratinocyte telomere dysfunction in human ageing and disease. Indeed, serum S100A7 protein levels have been reported to be associated with squamous and large cell carcinomas of the lung in a cell type-specific manner . The association of S100A7 protein with squamous cell carcinoma is something of a paradox as these cancers would very likely have deregulated telomerase  and reduced telomere dysfunction  in the immortal cells of the tumour. Furthermore, we have previously reported that the ectopic expression of telomerase in p16INK4A-deficient dysplastic keratinocytes can reverse the upregulation of S100A7 following telomere attrition and senescence ; also, many telomerase-positive immortal keratinocyte lines have reduced levels of S100A7 transcript (Hunter, Thurlow and Parkinson - unpublished data). However, significant levels of anaphase bridges and very short average telomere lengths have been reported in many human cancers, including squamous cell carcinomas [50, 51], suggesting that considerable telomere dysfunction exists in portions of these telomerase-positive tumours.
At present, we can only speculate on the mechanism by which telomere uncapping upregulates S100A7, but recent data has suggested that the S100 proteins can be positively regulated by the histone demethylase JMJD3 in foetal human keratinocytes by repressing the H3K27me3 marks , and the histone demethylase LSD1 is required for estrogen-dependent S100A7 gene expression in human breast cancer cells . Interestingly, telomere shortening and uncapping in telomerase-deficient mice also downregulates H3K27me3 and globally derepresses the genome , and therefore, the regulation of chromatin by telomere uncapping may offer a potential explanation for our results and the observation that telomerase can affect organismal ageing and healthspan when targeted only to epithelia as secreted proteins from cells with short telomeres could influence other organs in a paracrine manner .
In summary, we have shown here that several gene transcripts (ICEBERG, HOPX, S100A7 and S100A15) are upregulated following telomere uncapping in human keratinocytes independently of the DDR, and in the case of S100A7, this was also independent of cell cycle effectors such as p16INK4A, suggesting that the secreted form of S100A7 is a keratinocyte-specific SASP with the potential to non-invasively detect keratinocytes with dysfunctional telomeres.
Normal human epidermal keratinocytes, strain NHEK-131 (GIBCO-Invitrogen, Paisley, UK), were derived from a pool of a minimum of three neonatal foreskins and obtained at 6.8 mean population doublings (MPDs). Keratinocytes were cultured at 37°C in a 10% CO2/90% air with lethally irradiated 3T3 feeder cells in flavin-adenine enriched medium (FAD-). FAD- consists of 3 parts DMEM 4.5 g/L glucose (Lonza, Slough, UK), 1 part Ham’s F12 (Lonza), 10% (v/v) Hyclone Fetalclone II serum (Fisher Scientific, Loughborough, UK), 20 mM HEPES buffer (Lonza), 100 U/ml penicillin, 100 U/ml streptomycin (Lonza) and 2 mM L-Glutamine (Lonza), supplemented with 1.8 × 10-4 M Adenine (Sigma-Aldrich, Poole, Dorset, UK), 5 μg/ml insulin (Sigma-Aldrich), 5 μg/ml transferrin (Sigma-Aldrich), 0.4 μg/ml hydrocortisone (Sigma-Aldrich) and 8.4 ng/ml cholera toxin (Fisher Scientific, Loughborough, UK). Medium was replenished every third or fourth day with FAD+ complete medium, which consists of FAD- supplemented with 10 ng/ml of epidermal growth factor (Sigma-Aldrich).
Cells were irradiated using a GSR D1 Cs-137 low dose-rate gamma irradiator (GSM, Leipzig, Germany) at 1.493 gray/min for 1 min 20 s for a total dose of 2 gray with a recovery period of 6 h or at 1.493 gray/min for 13 min 23 s for a total dose of 20 gray and 0.747 gray/min for 13 min 23 s for a total dose of 10 gray, both with a recovery period of 5 days.
Retroviral vectors pLPC-N MYC (12540 Addgene, Cambridge, MA.) and pLPC-NMYC TRF2ΔBΔM (16069 Addgene) were donated by Titia de Lange (Rockefeller University, NYC, USA); pBABE-puro p14ARF, pBABE-puro p16INK4a and pBABE-puro p53 were donated by Gordon Peters (London Research Institute, CRUK, London, UK); and pBABE-puro GFP was donated by Cleo Bishop (Blizard Institute, QMUL, London, UK). Vector DNA was amplified in XL1-Blue Competent Cells (Stratagene, La Jolla, CA, USA) and purified with the Plasmid DNA purification Maxi kit (Qiagen, Manchester, UK) according to manufacturer’s instructions. Retroviral supernatants were produced by transfecting plasmid DNA into Phoenix A packaging cells (Nolan Labs, Stanford, USA) using FuGENE®6 transfection reagent (Roche) at a 1 μg DNA to 2.5 μl FuGENE®6 ratio. Next, amphotropic supernatants were used to infect keratinocytes (after removing feeders) with two consecutive rounds of centrifugation at 300 rpm for 1 h at 32°C (spinfection), 6 h apart, in the presence of 5 ug/ml polybrene (Sigma-Aldrich) to facilitate viral uptake. Retroviral supernatant was replaced with FAD medium and transduced keratinocytes were kept under normal culture conditions in the presence of irradiated 3T3 ‘feeders’. Mock-transduced plates were treated with polybrene only. Puromycin (Sigma-Aldrich) selection (1 μg/ml) was introduced 24 h later and kept for 72 h following the 24-h period allowed for gene expression at which point the mock plates were dead. Selective medium was then replaced with FAD overnight and cell pellets collected by centrifugation.
Extraction of total RNA was performed using the RNeasy Mini Kit (Qiagen) according to manufacturer’s instructions, including sample homogenisation with QIAshredder (Qiagen) and DNase treatment with the RNase-free DNase Set (Qiagen). Purified RNA was reverse transcribed using with Finnzymes DyNAmo™ cDNA Synthesis Kit (New England BioLabs, Hitchin, UK) and the cDNA stored at -20°C. RT quantitative real-time PCR (absolute copy number quantification using standard curve for each gene) was performed using SYBR® green I Master (hot-start Taq polymerase master mix) in the LightCycler 480® qPCR system (Roche Applied Science, Welwyn Garden City, Herts., UK). Target gene relative expression levels were calculated in relation to keratinocyte reference genes POLR2A and YAP1 using the LightCycler 480® Relative Quantification Software (with built-in multiple reference genes normalisation algorithm).
Primers used were, CCNA2 fwd CCATACCTCAAGTATTTGCCATC and CCNA2 rev TCCAGTCTTTCGTATTAATGATTCAG for CCNA2 cyclin A2 [GenBank: NM_001237.3]; CCND1 fwd CGTGGCCTCTAAGATGAAGG and CCND1 rev GTGTTCAATGAAATCGTGCG for CCND1 cyclin D1 [GenBank: NM_053056.2]; HIST2H2BE fwd GGTAGATCCACCCTTATGCTT and HIST2H2BE rev TTAAGAGGGGAACACCATGAG for HIST2H2BE histone cluster 2, H2be [GenBank: NM_003528.2]; HOPX fwd ACTTCAACAAGGTCGACAAGC and HOPX rev GGGTCTCCTCCTCGGAAA for HOPX HOP homeobox [GenBank: NM_139212.3; GenBank: NM_032495.5; GenBank: NM_001145460.1; GenBank: NM_001145459.1; GenBank: NM_139211.4]; ICEBERG fwd CTTGCTGGATTGCCTATTAGAG and ICEBERG rev TTGAGGGTCTTCTTCACAGAG for CARD18 caspase recruitment domain family, member 18 [GenBank: NM_021571.2]; IVL fwd TGCCTGAGCAAGAATGTGAG and IVL rev TTCCTCATGCTGTTCCCAGT for IVL involucrin [GenBank: NM_005547.2]; p14ARF fwd CTACTGAGGAGCCAGCGTCTA and p14ARF rev CTGCCCATCATCATGACCT for CDKN2A cyclin-dependent kinase inhibitor 2A, variant 4 or beta [GenBank: NM_058195.2]; p16INK4A fwd CCAACGCACCGAATAGTTACG and p16INK4A rev GCGCTGCCCATCATCATG for CDKN2A cyclin-dependent kinase inhibitor 2A, variant 1 or alpha [GenBank: NM_000077.3]; p21WAF1 fwd TCACTGTCTTGTACCCTTGTGC and p21WAF1 rev GGCGTTTGGAGTGGTAGAAA for CDKN1A cyclin-dependent kinase inhibitor 1A [GenBank: NM_000389.3; GenBank: NM_078467.1]; p53 fwd AGGCCTTGGAACTCAAGGAT and p53 rev CCCTTTTTGGACTTCAGGTG for TP53 tumour protein p53 [GenBank: NM_000546.4; GenBank: NM_001126114.4; GenBank: NM_001126113.1; GenBank: NM_001126112.1; GenBank: NM_001126115.1; GenBank: NM_001126116.1; GenBank: NM_001126117.1]; POLR2A fwd GCAAATTCACCAAGAGAGACG and POLR2A rev CACGTCGACAGGAACATCAG for POLR2A polymerase (RNA) II (DNA directed) polypeptide A [GenBank: NM_000937.3]; S100A7 fwd AGACGTGATGACAAGATTGAC and S100A7 rev TGTCTTTTTTCTCAAAGACGTC for S100A7 S100 calcium-binding protein A7 [GenBank: NM_002963.3]; S100A15 fwd ACGTCACTCCTGTCTCTCTTTACT and S100A15 rev TGATGAATCAACCCATTTCCTGGG for S100A7A S100 calcium-binding protein A7A [GenBank: NM_176823.3]; and S100A7/S100A15 fwd AAAGCAAAGATGAGCAACAC and S100A7/S100A15 rev AAGTTCTCCTTCATCATCGTC for co-amplification of both; TRF2 fwd CCAGATGAAGACAGTACAACCAA and TRF2 rev CCAGTTTCCTTCCCCATATTT for TERF2 telomeric repeat binding factor 2 [GenBank: NM_005652.2]; TRF2DN fwd GTTGATTTCTGAAGAAGATTTGTT and TRF2DN rev GTGGAAGTAGAACTTGAGCAC for TRF2 ΔBΔM ; YAP1 fwd CCCAGATGAACGTCACAGC and YAP1 rev GATTCTCTGGTTCATGGCTGA for YAP1 Yes-associated protein 1 [GenBank: NM_000389.3; GenBank: NM_078467.1]. S100A7/S100A15 primers  amplify highly homologous transcripts for S100A7 (psoriasin) and S100A15 (koebnerisin). S100A7-specific and S100A15-specific primers were designed to independently quantify each transcript . HOPX primers were designed to amplify all five transcript variants described for this gene. The design of a specific primer set for amplification of exogenous TRF2 ΔBΔM was performed manually, the forward sequence directed at the myc tag (located upstream of the gene insert) and the reverse sequence targeting the TRF2 ΔBΔM transgene in the retroviral construct. We have validated that all primer pairs are highly specific for the expected product without cross-amplification. All qPCR results were repeated as three complete experiments with two to three replicates each unless otherwise stated.
Cells were lysed with M-PER® Mammalian Protein Extraction Reagent (Thermo Scientific) and cOmplete Mini EDTA-free protease inhibitor cocktail tablets (Roche). Mixture was gently shaken for 10 min at room temperature and cell debris removed by centrifugation at 14,000 g for 15 min. Supernatant was collected and kept on ice before being stored at -80°C. Protein concentration in the cell lysates was measured using the DC™ Protein Assay (BioRad, Hertfordshire, UK). Protein samples for Western blotting were prepared by adding 1x NuPAGE® LDS Sample Buffer (Life Technologies) followed by denaturation for 5 min at 100°C. Proteins were loaded onto NuPAGE® 10% Bis-Tris precast resolving gels (Invitrogen) and separated by gel electrophoresis at 130 V on 1x NuPAGE® running buffer (Invitrogen). Transfer to Immobilon™ PVDF membranes (Millipore, Watford, UK) was performed on transfer buffer (25 mM Tris, 190 mM glycine and 20% methanol) at 30 V for 90 min at 4°C. Membranes were blocked in 5% non-fat milk in Tris-buffered saline/Tween® 20 (TBS-T: 1 M Tris, pH 8.0; 5 M NaCl; 0.1% Tween® 20) for 1 h at room temperature. Next, membranes were probed with primary antibodies in 5% non-fat milk in TBS-T overnight at 4°C followed by incubation with HRP-conjugated secondary antibodies, prepared in 5% non-fat milk in TBS-T, for 1 h at room temperature. Immunodetection was performed with Amersham™ ECL Plus chemiluminescent detection system (GE Healthcare Life Sciences) and visualised on Amersham™ ECL Hyperfilm (GE Healthcare Life Sciences, Chalfont St. Giles, Bucks, UK). Primary antibodies used were mouse monoclonal anti-human p21WAF1(C70) at 1:250 dilution (610233 BD Transduction Labs), mouse monoclonal anti-human p53 (DO-1) at 1:250 dilution (sc-126 Santa Cruz Biotechnology, CA), mouse monoclonal anti-human psoriasin/HID5/S100A7 at 1:1,000 dilution (IMG-409A Imgenex, San Diego, CA) and rabbit polyclonal anti-human GAPDH at 1:1,000 dilution (ab9485 Abcam Cambridge, UK). Secondary antibodies used were polyclonal goat anti-mouse IgG HRP-conjugated at 1:2,500 dilution (Fisher Scientific) and polyclonal goat anti-rabbit IgG HRP-conjugated at 1:2,500 dilution (Fisher Scientific).
In the UK commercially derived human cells are not subject to further ethical approval by the purchaser and once passaged they are regarded as a cell line and exempt.
DNA damage response
Dulbecco’s modified Eagle’s medium
DNA double strand break
flavin-adenine enriched medium
irreparable DNA double strand break
mean population doubling
normal human epidermal keratinocyte
oral squamous cell carcinoma
senescence-associated secretory phenotype
- TRF2 or TERF2:
telomeric repeat binding factor 2
- TRF2DN or TRF2ΔBΔM:
dominant-negative TRF2 or TRF2 delta B delta M.
We wish to thank Titia de Lange, Gordon Peters and Cleo Bishop for the gifts of retroviral vectors. Alice de Castro was supported by a Research into Ageing (Age UK) PhD studentship.
- Coppe JP, Patil CK, Rodier F, Sun Y, Munoz DP, Goldstein J, Nelson PS, Desprez PY, Campisi J: Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008, 6: 2853-2868.View ArticlePubMedGoogle Scholar
- Kuilman T, Peeper DS: Senescence-messaging secretome: SMS-ing cellular stress. Nat Rev Cancer. 2009, 9: 81-94. 10.1038/nrc2560.View ArticlePubMedGoogle Scholar
- Jiang H, Schiffer E, Song Z, Wang J, Zurbig P, Thedieck K, Moes S, Bantel H, Saal N, Jantos J, Brecht M, Jeno P, Hall MN, Hager K, Manns MP, Hecker H, Ganser A, Dohner K, Bartke A, Meissner C, Mischak H, Ju Z, Rudolph KL: Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A. 2008, 105: 11299-11304. 10.1073/pnas.0801457105.PubMed CentralView ArticlePubMedGoogle Scholar
- Harley CB, Futcher AB, Greider CW: Telomeres shorten during ageing of human fibroblasts. Nature. 1990, 345: 458-460. 10.1038/345458a0.View ArticlePubMedGoogle Scholar
- De Lange T: How shelterin solves the telomere end-protection problem. Cold Spring Harb Symp Quant Biol. 2010, 75: 167-177. 10.1101/sqb.2010.75.017.View ArticlePubMedGoogle Scholar
- De Lange T: Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005, 19: 2100-2110. 10.1101/gad.1346005.View ArticlePubMedGoogle Scholar
- Olovnikov AM: A theory of marginotomy. The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol. 1973, 41: 181-190. 10.1016/0022-5193(73)90198-7.View ArticlePubMedGoogle Scholar
- Watson JD: Origin of concatemeric T7 DNA. Nat New Biol. 1972, 239: 197-201.View ArticlePubMedGoogle Scholar
- Makarov VL, Hirose Y, Langmore JP: Long G tails at both ends of human chromosomes suggest a C strand degradation mechanism for telomere shortening. Cell. 1997, 88: 657-666. 10.1016/S0092-8674(00)81908-X.View ArticlePubMedGoogle Scholar
- Petersen S, Saretzki G, Von Zglinicki T: Preferential accumulation of single-stranded regions in telomeres of human fibroblasts. Exp Cell Res. 1998, 239: 152-160. 10.1006/excr.1997.3893.View ArticlePubMedGoogle Scholar
- Von Zglinicki T, Saretzki G, Docke W, Lotze C: Mild hyperoxia shortens telomeres and inhibits proliferation of fibroblasts: a model for senescence?. Exp Cell Res. 1995, 220: 186-193. 10.1006/excr.1995.1305.View ArticlePubMedGoogle Scholar
- Takai H, Smogorzewska A, De Lange T: DNA damage foci at dysfunctional telomeres. Curr Biol. 2003, 13: 1549-1556. 10.1016/S0960-9822(03)00542-6.View ArticlePubMedGoogle Scholar
- D’Adda Di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP: A DNA damage checkpoint response in telomere-initiated senescence. Nature. 2003, 426: 194-198. 10.1038/nature02118.View ArticlePubMedGoogle Scholar
- Fumagalli M, Rossiello F, Clerici M, Barozzi S, Cittaro D, Kaplunov JM, Bucci G, Dobreva M, Matti V, Beausejour CM, Herbig U, Longhese MP, D’Adda Di Fagagna F: Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat Cell Biol. 2012, 14: 355-365. 10.1038/ncb2466.PubMed CentralView ArticlePubMedGoogle Scholar
- Hewitt G, Jurk D, Marques FD, Correia-Melo C, Hardy T, Gackowska A, Anderson R, Taschuk M, Mann J, Passos JF: Telomeres are favoured targets of a persistent DNA damage response in ageing and stress-induced senescence. Nat Commun. 2012, 3: 708-PubMed CentralView ArticlePubMedGoogle Scholar
- Mao L, El-Naggar AK, Fan YH, Lee JS, Lippman SM, Kayser S, Lotan R, Hong WK: Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res. 1996, 56: 5600-5604.PubMedGoogle Scholar
- Rheinwald JG, Hahn WC, Ramsey MR, Wu JY, Guo Z, Tsao H, De Luca M, Catricala C, O’Toole KM: A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol. 2002, 22: 5157-5172. 10.1128/MCB.22.14.5157-5172.2002.PubMed CentralView ArticlePubMedGoogle Scholar
- Suram A, Kaplunov J, Patel PL, Ruan H, Cerutti A, Boccardi V, Fumagalli M, Di Micco R, Mirani N, Gurung RL, Hande MP, D’Adda Di Fagagna F, Herbig U: Oncogene-induced telomere dysfunction enforces cellular senescence in human cancer precursor lesions. EMBO J. 2012, 31: 2839-2851. 10.1038/emboj.2012.132.PubMed CentralView ArticlePubMedGoogle Scholar
- Giangreco A, Qin M, Pintar JE, Watt FM: Epidermal stem cells are retained in vivo throughout skin aging. Aging Cell. 2008, 7: 250-259. 10.1111/j.1474-9726.2008.00372.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Sharpless NE, DePinho RA: How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol. 2007, 8: 703-713. 10.1038/nrm2241.View ArticlePubMedGoogle Scholar
- Barrandon Y, Green H: Three clonal types of keratinocyte with different capacities for multiplication. Proc Natl Acad Sci U S A. 1987, 84: 2302-2306. 10.1073/pnas.84.8.2302.PubMed CentralView ArticlePubMedGoogle Scholar
- Lindsey J, McGill NI, Lindsey LA, Green DK, Cooke HJ: In vivo loss of telomeric repeats with age in humans. Mutat Res. 1991, 256: 45-48. 10.1016/0921-8734(91)90032-7.View ArticlePubMedGoogle Scholar
- Nakamura K, Izumiyama-Shimomura N, Sawabe M, Arai T, Aoyagi Y, Fujiwara M, Tsuchiya E, Kobayashi Y, Kato M, Oshimura M, Sasajima K, Nakachi K, Takubo K: Comparative analysis of telomere lengths and erosion with age in human epidermis and lingual epithelium. J Invest Dermatol. 2002, 119: 1014-1019. 10.1046/j.1523-1747.2002.19523.x.View ArticlePubMedGoogle Scholar
- Sugimoto M, Yamashita R, Ueda M: Telomere length of the skin in association with chronological aging and photoaging. J Dermatol Sci. 2006, 43: 43-47. 10.1016/j.jdermsci.2006.02.004.View ArticlePubMedGoogle Scholar
- Ressler S, Bartkova J, Niederegger H, Bartek J, Scharffetter-Kochanek K, Jansen-Durr P, Wlaschek M: p16INK4A is a robust in vivo biomarker of cellular aging in human skin. Aging Cell. 2006, 5: 379-389. 10.1111/j.1474-9726.2006.00231.x.View ArticlePubMedGoogle Scholar
- Waaijer ME, Parish WE, Strongitharm BH, Van Heemst D, Slagboom PE, De Craen AJ, Sedivy JM, Westendorp RG, Gunn DA, Maier AB: The number of p16INK4a positive cells in human skin reflects biological age. Aging Cell. 2012, 11: 722-725. 10.1111/j.1474-9726.2012.00837.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Smogorzewska A, De sLange T: Different telomere damage signaling pathways in human and mouse cells. EMBO J. 2002, 21: 4338-4348. 10.1093/emboj/cdf433.PubMed CentralView ArticlePubMedGoogle Scholar
- Minty F, Thurlow JK, Harrison PR, Parkinson EK: Telomere dysfunction in human keratinocytes elicits senescence and a novel transcription profile. Exp Cell Res. 2008, 314: 2434-2447. 10.1016/j.yexcr.2008.05.007.View ArticlePubMedGoogle Scholar
- Zhang H, Zhao Q, Chen Y, Wang Y, Gao S, Mao Y, Li M, Peng A, He D, Xiao X: Selective expression of S100A7 in lung squamous cell carcinomas and large cell carcinomas but not in adenocarcinomas and small cell carcinomas. Thorax. 2008, 63: 352-359. 10.1136/thx.2007.087015.View ArticlePubMedGoogle Scholar
- Wang J, Sun Q, Morita Y, Jiang H, Gross A, Lechel A, Hildner K, Guachalla LM, Gompf A, Hartmann D, Schambach A, Wuestefeld T, Dauch D, Schrezenmeier H, Hofmann WK, Nakauchi H, Ju Z, Kestler HA, Zender L, Rudolph KL: A differentiation checkpoint limits hematopoietic stem cell self-renewal in response to DNA damage. Cell. 2012, 148: 1001-1014. 10.1016/j.cell.2012.01.040.View ArticlePubMedGoogle Scholar
- Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, Campisi J: Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol. 2009, 11: 973-979. 10.1038/ncb1909.PubMed CentralView ArticlePubMedGoogle Scholar
- Dulic V, Drullinger LF, Lees E, Reed SI, Stein GH: Altered regulation of G1 cyclins in senescent human diploid fibroblasts: accumulation of inactive cyclin E-Cdk2 and cyclin D1-Cdk2 complexes. Proc Natl Acad Sci U S A. 1993, 90: 11034-11038. 10.1073/pnas.90.23.11034.PubMed CentralView ArticlePubMedGoogle Scholar
- Topley GI, Okuyama R, Gonzales JG, Conti C, Dotto GP: p21(WAF1/Cip1) functions as a suppressor of malignant skin tumor formation and a determinant of keratinocyte stem-cell potential. Proc Natl Acad Sci U S A. 1999, 96: 9089-9094. 10.1073/pnas.96.16.9089.PubMed CentralView ArticlePubMedGoogle Scholar
- Missero C, Di Cunto F, Kiyokawa H, Koff A, Dotto GP: The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. Genes Dev. 1996, 10: 3065-3075. 10.1101/gad.10.23.3065.View ArticlePubMedGoogle Scholar
- Wolf R, Mirmohammadsadegh A, Walz M, Lysa B, Tartler U, Remus R, Hengge U, Michel G, Ruzicka T: Molecular cloning and characterization of alternatively spliced mRNA isoforms from psoriatic skin encoding a novel member of the S100 family. FASEB J. 2003, 17: 1969-1971.PubMedGoogle Scholar
- Wolf R, Ruzicka T, Yuspa SH: Novel S100A7 (psoriasin)/S100A15 (koebnerisin) subfamily: highly homologous but distinct in regulation and function. Amino Acids. 2011, 41: 789-796. 10.1007/s00726-010-0666-4.View ArticlePubMedGoogle Scholar
- Panier S, Ichijima Y, Fradet-Turcotte A, Leung CC, Kaustov L, Arrowsmith CH, Durocher D: Tandem protein interaction modules organize the ubiquitin-dependent response to DNA double-strand breaks. Mol Cell. 2012, 47: 383-395. 10.1016/j.molcel.2012.05.045.View ArticlePubMedGoogle Scholar
- Shiloh Y, Shema E, Moyal L, Oren M: RNF20-RNF40: a ubiquitin-driven link between gene expression and the DNA damage response. FEBS Lett. 2011, 585: 2795-2802. 10.1016/j.febslet.2011.07.034.View ArticlePubMedGoogle Scholar
- Muntoni A, Fleming J, Gordon KE, Hunter K, McGregor F, Parkinson EK, Harrison PR: Senescing oral dysplasias are not immortalized by ectopic expression of hTERT alone without other molecular changes, such as loss of INK4A and/or retinoic acid receptor-beta: but p53 mutations are not necessarily required. Oncogene. 2003, 22: 7804-7808. 10.1038/sj.onc.1207085.View ArticlePubMedGoogle Scholar
- Coppe JP, Rodier F, Patil CK, Freund A, Desprez PY, Campisi J: Tumor suppressor and aging biomarker p16(INK4a) induces cellular senescence without the associated inflammatory secretory phenotype. J Biol Chem. 2011, 286: 36396-36403. 10.1074/jbc.M111.257071.PubMed CentralView ArticlePubMedGoogle Scholar
- Blanco R, Munoz P, Flores JM, Klatt P, Blasco MA: Telomerase abrogation dramatically accelerates TRF2-induced epithelial carcinogenesis. Genes Dev. 2007, 21: 206-220. 10.1101/gad.406207.PubMed CentralView ArticlePubMedGoogle Scholar
- Biroccio A, Cherfils-Vicini J, Augereau A, Pinte S, Bauwens S, Ye J, Simonet T, Horard B, Jamet K, Cervera L, Mendez-Bermudez A, Poncet D, Grataroli R, De Rodenbeeke CT, Salvati E, Rizzo A, Zizza P, Ricoul M, Cognet C, Kuilman T, Duret H, Lepinasse F, Marvel J, Verhoeyen E, Cosset FL, Peeper D, Smyth MJ, Londono-Vallejo A, Sabatier L, Picco V, Pages G, Scoazec JY, Stoppacciaro A, Leonetti C, Vivier E, Gilson E: TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells. Nat Cell Biol. 2013, 15: 818-828. 10.1038/ncb2774.View ArticlePubMedGoogle Scholar
- Loughran O, Malliri A, Owens D, Gallimore PH, Stanley MA, Ozanne B, Frame MC, Parkinson EK: Association of CDKN2A/p16INK4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Oncogene. 1996, 13: 561-568.PubMedGoogle Scholar
- Hattinger E, Zwicker S, Ruzicka T, Yuspa SH, Wolf R: Opposing functions of psoriasin (S100A7) and koebnerisin (S100A15) in epithelial carcinogenesis. Curr Opin Pharmacol. 2013, 13: 588-594. 10.1016/j.coph.2013.04.007.View ArticlePubMedGoogle Scholar
- Deol YS, Nasser MW, Yu L, Zou X, Ganju RK: Tumor-suppressive effects of psoriasin (S100A7) are mediated through the beta-catenin/T cell factor 4 protein pathway in estrogen receptor-positive breast cancer cells. J Biol Chem. 2011, 286: 44845-44854. 10.1074/jbc.M111.225466.PubMed CentralView ArticlePubMedGoogle Scholar
- Hattori F, Kiatsurayanon C, Okumura K, Ogawa H, Ikeda S, Okamoto K, Niyonsaba F: The antimicrobial protein S100A7/psoriasin enhances expression of keratinocyte differentiation markers and strengthens the skin tight junction barrier. Br J Dermatol. 2014, ᅟ: ᅟ-doi:10.1111/bjd.13125. [Epub ahead of print]Google Scholar
- Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K, Enk A, Arnold B, Bierhaus A, Nawroth PP, Hess J, Angel P: RAGE signaling sustains inflammation and promotes tumor development. J Exp Med. 2008, 205: 275-285. 10.1084/jem.20070679.PubMed CentralView ArticlePubMedGoogle Scholar
- Freund A, Patil CK, Campisi J: p38MAPK is a novel DNA damage response-independent regulator of the senescence-associated secretory phenotype. EMBO J. 2011, 30: 1536-1548. 10.1038/emboj.2011.69.PubMed CentralView ArticlePubMedGoogle Scholar
- Pitiyage GN, Slijepcevic P, Gabrani A, Chianea YG, Lim KP, Prime SS, Tilakaratne WM, Fortune F, Parkinson EK: Senescent mesenchymal cells accumulate in human fibrosis by a telomere-independent mechanism and ameliorate fibrosis through matrix metalloproteinases. J Pathol. 2011, 223: 604-617. 10.1002/path.2839.View ArticlePubMedGoogle Scholar
- Gordon KE, Ireland H, Roberts M, Steeghs K, McCaul JA, MacDonald DG, Parkinson EK: High levels of telomere dysfunction bestow a selective disadvantage during the progression of human oral squamous cell carcinoma. Cancer Res. 2003, 63: 458-467.PubMedGoogle Scholar
- Parris CN, Jezzard S, Silver A, MacKie R, McGregor JM, Newbold RF: Telomerase activity in melanoma and non-melanoma skin cancer. Br J Cancer. 1999, 79: 47-53. 10.1038/sj.bjc.6690010.PubMed CentralView ArticlePubMedGoogle Scholar
- Gschwandtner M, Zhong S, Tschachler A, Mlitz V, Karner S, Elbe-Burger A, Mildner M: Fetal human keratinocytes produce large amounts of antimicrobial peptides: involvement of histone-methylation processes. J Invest Dermatol. 2014, 134: 2192-2201. 10.1038/jid.2014.165.PubMed CentralView ArticlePubMedGoogle Scholar
- Yu SE, Jang YK: The histone demethylase LSD1 is required for estrogen-dependent S100A7 gene expression in human breast cancer cells. Biochem Biophys Res Commun. 2012, 427: 336-342. 10.1016/j.bbrc.2012.09.057.View ArticlePubMedGoogle Scholar
- Schoeftner S, Blanco R, Lopez De Silanes I, Munoz P, Gomez-Lopez G, Flores JM, Blasco MA: Telomere shortening relaxes X chromosome inactivation and forces global transcriptome alterations. Proc Natl Acad Sci U S A. 2009, 106: 19393-19398. 10.1073/pnas.0909265106.PubMed CentralView ArticlePubMedGoogle Scholar
- Tomas-Loba A, Flores I, Fernandez-Marcos PJ, Cayuela ML, Maraver A, Tejera A, Borras C, Matheu A, Klatt P, Flores JM, Vina J, Serrano M, Blasco MA: Telomerase reverse transcriptase delays aging in cancer-resistant mice. Cell. 2008, 135: 609-622. 10.1016/j.cell.2008.09.034.View ArticlePubMedGoogle Scholar
- Gemenetzidis E, Bose A, Riaz AM, Chaplin T, Young BD, Ali M, Sugden D, Thurlow JK, Cheong SC, Teo SH, Wan H, Waseem A, Parkinson EK, Fortune F, Teh MT: FOXM1 upregulation is an early event in human squamous cell carcinoma and it is enhanced by nicotine during malignant transformation. PLoS One. 2009, 4: e4849-10.1371/journal.pone.0004849.PubMed CentralView ArticlePubMedGoogle Scholar
- Wolf R, Howard OM, Dong HF, Voscopoulos C, Boeshans K, Winston J, Divi R, Gunsior M, Goldsmith P, Ahvazi B, Chavakis T, Oppenheim JJ, Yuspa SH: Chemotactic activity of S100A7 (psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J Immunol. 2008, 181: 1499-1506. 10.4049/jimmunol.181.2.1499.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.